celares GmbH is a privately owned company, established in 2003, and a recognized leader in the field of bioconjugation/half-life extension by chemical modification and the synthesis of polymers for drug delivery. The company provides high-quality customized services, including feasibility studies, up-scaling and process development, as well as the development and validation of required analytical methods. Celares also offers pilot GMP production of bioconjugates and functionalized polymers used as excipients in drug formulation. Moreover, celares has developed innovative technologies, including multiplexing technologies that allow the construction of homo- (celaSTAR) and heteromultimeric (PaSmax®) conjugates and biologics, and celaCLICK, a surface coating technology.
Our clients are big and medium sized pharmaceutical companies, but also innovative biotech companies, biosimilar developers and diagnostic companies from all over the world. Flexibility, know-how, and outside-of-the-box thinking enables us to appropriately address clients needs related to the application of their particular drug or biomolecule. celares GmbH combines decades of chemical and biotechnological experience within the company and offers customers the possibility to acquire forward-looking technologies at a reasonable price. The optimization of polymer based conjugations and formulations as well as manufacturing processes of your drug compound is part of our contract development.
View profiles of the management team at celares GmbH
Press releases & Publications
Read press releases, articles, and download brochures and flyers
Partners & References
See a list of selected partners and exemplary customers.
Our commitment to high-quality custom conjugation services.
celares GmbH is an independent company and guarantees the complete confidentiality and freedom to operate that a pharmaceutical company depends on. Based on long-term experience and excellent scientific know-how, celares accelerates customers’ development programs.